[Clinical observation of taxotere in the treatment of advanced non-small-cell lung cancer and breast cancer].
OBJECTIVE
To observe the response rate and toxic reaction of taxotere in the treatment of advanced NSCLC and breast cancer.


METHODS
A total of 24 cases was included in the study. Taxotere 75 mg/m2 i.v. drip for 1 hour; dexamethasone 8 mg bid 24 hour before taxotere, and continued for 3 days. For NSCLC, the taxotere was combined with DDP 90 mg/m2; for breast cancer, it was combined with ADM 40 mg/m2. The second treatment cycle was given after 3 weeks. At last 2 cycles were given.


RESULTS
In 15 NSCLC patients, there were 6 PR, 7 NC and 2 PD. In 9 breast cancer patients, there were 2 CR, 6 PR and 1 NC. The major toxic reactions were neutropenia, diarrhea, fatigue, muscle pain and alopecia. Grade 3 and grade 4 neutropenia occurred in 9 and 4 cases, respectively. Decrease in hemoglobin and thrombocytopenia were mild. Diarrhea occurred in 19 cases and allergic reaction in 1 case.


CONCLUSIONS
Taxotere is effective in the combined treatment of advanced NSCLC and breast cancer. The toxic reactions are tolerable.
Li
L
L
Department of Oncology, First Teaching Hospital, Dalian Medical University, Dalian 116011, China.
Zou
Y
Y
Guan
X
X
D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D043823:Taxoids; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel